Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
80.86%
↑ 1022% above average
Average (39q)
-8.77%
Historical baseline
Range
High:80.86%
Low:-312.66%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 80.86% |
| Q2 2025 | -204.07% |
| Q1 2025 | -27.30% |
| Q4 2024 | -33.07% |
| Q3 2024 | 34.55% |
| Q2 2024 | 11.92% |
| Q1 2024 | -4.70% |
| Q4 2023 | 5.12% |
| Q3 2023 | -33.46% |
| Q2 2023 | 24.36% |
| Q1 2023 | -0.05% |
| Q4 2022 | -26.43% |
| Q3 2022 | -24.02% |
| Q2 2022 | 33.80% |
| Q1 2022 | 77.35% |
| Q4 2021 | -312.66% |
| Q3 2021 | 3.35% |
| Q2 2021 | -0.43% |
| Q1 2021 | -19.86% |
| Q4 2020 | 12.54% |
| Q3 2020 | -5.05% |
| Q2 2020 | 13.93% |
| Q1 2020 | -8.24% |
| Q4 2019 | 18.40% |
| Q3 2019 | 22.17% |
| Q2 2019 | 15.20% |
| Q1 2019 | -26.26% |
| Q4 2018 | 2.41% |
| Q3 2018 | -13.27% |
| Q2 2018 | 24.97% |
| Q1 2018 | -27.44% |
| Q4 2017 | -0.53% |
| Q3 2017 | 7.80% |
| Q2 2017 | 8.38% |
| Q1 2017 | -0.08% |
| Q4 2016 | -17.77% |
| Q3 2016 | 33.66% |
| Q2 2016 | 39.38% |
| Q1 2016 | -9.48% |
| Q4 2015 | -26.87% |